Abrax Japan, Inc
- Biotech or pharma, therapeutic R&D
Abrax Japan, Inc. is a preclinical-stage biotechnology company developing a novel class of therapeutics that harness skin-derived hormones to treat obesity and lipid disorders. By targeting the skin as a systemic "endocrine"organ, Abrax is pioneering non-invasive, topical treatments counteracting obesity and obesity-related comorbidities by stimulating fat metabolism and promoting sebum secretion to lose fat through the skin. The company’s lead candidate, based on a reformulated version of an approved dermatologic drug, is designed to deliver systemic metabolic benefits through a patient-friendly lotion. Founded in 2020 and backed by venture capital, Abrax holds exclusive licenses from the University of Pennsylvania and is preparing for first-in-human clinical studies.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}